Outlook Therapeutics (OTLK)

P/S ratio as of January 2026 (TTM): 23.0

According to Outlook Therapeutics 's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is -0.9310. At the end of 2025 the company had a P/S ratio of 45.5.

P/S ratio history for Outlook Therapeutics from 2016 to 2025

PS ratio at the end of each year

Year	P/S ratio	Change
2025	45.5
2024	N/A
2023	N/A
2022	N/A
2021	N/A
2020	N/A	-100%
2019	3.20	-74.53%
2018	12.6	62.18%
2017	7.75	-75%
2016	31.0

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Novocure NVCR	2.40	-89.56%	Jersey
Novavax NVAX	1.30	-94.35%	🇺🇸 USA
Organovo ONVO	25.5	10.87%	🇺🇸 USA
Orchard Therapeutics ORTX	17.4	-24.32%	🇬🇧 UK

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Outlook Therapeutics (OTLK)

P/S ratio as of January 2026 (TTM): 23.0